Biopharmaceutical companies launched 42 initial public offerings in the US in 2017 versus 30 in 2016 as stock values rose. But biotechnology in general endured a rough fourth quarter, raising the question of whether returns will be high enough to support as many or more IPOs in 2018.
The average return for the biopharma IPO class of 2017 as of Dec. 29 – last year's final day of trading – was 33.2%, which was a near tripling of the 11.2% return at the end of 2016 for therapeutics firms that went public in the US that year
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
